ASCO Genitourinary Cancers Symposium | Conference

Merseburger Reflects on Data Presented at 2022 ASCO GU in Prostate Cancer
March 14, 2022

Axel Merseburger, MD, PhD, looked back on 2022 ASCO GU and the new data presented for the treatment of prostate cancer.

Daniel M. Geynisman, MD, on Optimal Therapy Selection in RCC
March 11, 2022

At 2022 ASCO GU, Daniel M. Geynisman, MD, spoke with CancerNetwork® about his strategy for treating renal cell carcinoma across lines of therapy.

Choueiri Discusses Results of CLEAR Substudy of Lenvatinib Plus Pembrolizumab in RCC
March 04, 2022

At 2022 ASCO GU, Toni K. Choueiri, MD, discussed the CLEAR study and how East Asian patients with renal cell carcinoma derived similar benefit with lenvatinib plus pembrolizumab as the overall trial population.

Efstathiou Discusses Positive Outcomes in HRR+ mCRPC With Niraparib Combo in MAGNITUDE Trial
February 25, 2022

Eleni Efstathiou, MD, PhD, spoke about the positive results seen in the phase 3 MAGNITUDE trial in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations who were treated with a niraparib-containing regimen.

Merseburger Offers PRESIDE Trial Overview of Continuous Enzalutamide in mCRPC
February 23, 2022

Axel Merseburger, MD, PhD, spoke key results of the PRESIDE trial, which examined continuous enzalutamide to treat patients with metastatic castration-resistant prostate cancer and progressive disease.

Immunotherapy in the Frontline Demonstrates Promise in mRCC With Poor Performance Status
February 23, 2022

Patients with metastatic renal cell carcinoma and a performance status of 2 or more experienced promising clinical activity from treatment with nivolumab/ipilimumab and pembrolizumab/axitinib.

Adrenocortical Carcinoma at Low/Intermediate Recurrence Risk Does Not Benefit From Postoperative Adjuvant Mitotane
February 21, 2022

Efficacy of adjuvant mitotane for patients with adrenocortical carcinoma following surgery was presented at 2022 ASCO GU.

No Significant PFS Improvement Noted in Advanced Squamous Cell Penile Cancer Treated With Immunotherapy
February 21, 2022

Data from a phase 2 trial of atezolizumab with or without radiotherapy showed some antitumor activity in advanced squamous cell carcinoma of the penis, despite failing to meet the primary end point of progression-free survival.

Disease-Free Survival Benefits Persist With Adjuvant Pembrolizumab in RCC
February 20, 2022

Updated data from the KEYNOTE-564 trial that were reported at 2022 ASCO GU show continuous disease-free survival advantage with pembrolizumab vs placebo as adjuvant therapy for renal cell carcinoma.

High-Risk Early RCC May Benefit from Neoadjuvant Avelumab Plus Axitinib
February 20, 2022

Data from the NeoAvAx trial presented at 2022 ASCO GU show potential for neoadjuvant avelumab plus axitinib for high-risk, non-metastatic clear-cell renal cell carcinoma.